EGFR and non-small cell lung carcinoma: Although third‐generation inhibitors are available in the clinic, lst‐generation EGFR‐TKIs, such as erlotinib and gefitinib, are still widely used in first‐line treatment of NSCLC patients with EGFR mutations.